{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:08:06Z","timestamp":1774566486615,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaccas.2025.106555","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T19:58:17Z","timestamp":1771444697000},"page":"106555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Permissive Cardiotoxicity in HER2-Positive Metastatic Breast Cancer With Moderate Left Ventricular Dysfunction"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0570-0581","authenticated-orcid":false,"given":"Humza","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramukh","family":"Arun Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-9340","authenticated-orcid":false,"given":"Agnes S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaccas.2025.106555_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"21","key":"10.1016\/j.jaccas.2025.106555_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jaccas.2025.106555_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccas.2025.106555_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"41","key":"10.1016\/j.jaccas.2025.106555_bib5","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jaccas.2025.106555_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRT study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.jaccas.2025.106555_bib7","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1093\/oncolo\/oyad086","article-title":"Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jaccas.2025.106555_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-019-05139-6","article-title":"Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction","volume":"175","author":"Hussain","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccas.2025.106555_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jaccas.2025.106555_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492503342X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492503342X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T19:59:07Z","timestamp":1771444747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608492503342X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266608492503342X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.106555","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Permissive Cardiotoxicity in HER2-Positive Metastatic Breast Cancer With Moderate Left Ventricular Dysfunction","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.106555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"106555"}}